Market Place
Sourcing Support
Windtree Therapeutics to Release Istaroxime Study Interim Results
22 May 2025 //
GLOBENEWSWIRE
Windtree Shares Istaroxime Data at ESC Heart Failure Conference
19 May 2025 //
GLOBENEWSWIRE
Windtree Therapeutics Reports Q1 2025 Results and Business Update
16 May 2025 //
GLOBENEWSWIRE
Windtree Therapeutics Presents Preclinical Data on Istaroxime
12 May 2025 //
GLOBENEWSWIRE
Windtree announces Istaroxime exclusivity and IP strategy for US
06 May 2025 //
GLOBENEWSWIRE
Windtree Unveils Deal to Boost Revenue, Advance Drug Pipeline
01 May 2025 //
GLOBENEWSWIRE
Windtree Therapeutics Reports 2024 Financial Results & Updates
15 Apr 2025 //
GLOBENEWSWIRE
Windtree Therapeutics Complies with Nasdaq Listing Rules
24 Mar 2025 //
GLOBENEWSWIRE
Windtree to Partner with Small Biotech for FDA Approved Product
20 Mar 2025 //
GLOBENEWSWIRE
Windtree Secures Istaroxime Patent Allowance For Acute Heart Failure
04 Mar 2025 //
GLOBENEWSWIRE
Windtree files patent for istaroxime in India
27 Feb 2025 //
GLOBENEWSWIRE
Windtree Therapeutics, Inc. Announces Reverse Stock Split
18 Feb 2025 //
GLOBENEWSWIRE
Windtree To Present Istaroxime Data At Heart Failure Conference
12 Feb 2025 //
GLOBENEWSWIRE
Windtree Secures Important Japanese Patent For Cancer Research
17 Jan 2025 //
GLOBENEWSWIRE
Windtree Announces Addition of Leanne Kelly to Board of Directors
13 Jan 2025 //
GLOBENEWSWIRE
Windtree Adopts Strategy To Acquire FDA Assets, Advance Pipeline
08 Jan 2025 //
GLOBENEWSWIRE
Windtree Files New Istaroxime Patent for Myocardial Arrhythmia
09 Dec 2024 //
GLOBENEWSWIRE
Windtree Partners for Potential Strategic Deal in Cardiogenic Shock
04 Dec 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Reports Q3 2024 Financial Results & Updates
27 Nov 2024 //
GLOBENEWSWIRE
Windtree Announces Leadership Transition Plan
14 Nov 2024 //
GLOBENEWSWIRE
Windtree Expands Patents with Hong Kong Istaroxime Patent Issuance
04 Nov 2024 //
GLOBENEWSWIRE
Windtree Therapeutic Initiates Seismic C Study in Cardiogenic Shock
30 Oct 2024 //
GLOBENEWSWIRE
Windtree Announces Istaroxime Patent Filings Worldwide
23 Oct 2024 //
GLOBENEWSWIRE
Windtree To Present at the ThinkEquity Conference on October 30th
21 Oct 2024 //
GLOBENEWSWIRE
Windtree Expands Patents With Istaroxime Patent Issued In Japan
17 Oct 2024 //
GLOBENEWSWIRE
Windtree Announces Publication Of Istaroxime Phase 2b Design
09 Oct 2024 //
GLOBENEWSWIRE
Windtree Reports Ph 2b Results For Istaroxime In Heart Failure
30 Sep 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Announces Virtual Investor Day Presentation
26 Sep 2024 //
GLOBENEWSWIRE
Windtree’s shock med raises blood pressure in latest phase 2 win
26 Sep 2024 //
BIOSPACE
Windtree Completes Enrollment For Istaroxime Study
04 Sep 2024 //
GLOBENEWSWIRE
Despite cash infusion, Windtree still faces money running out within a year
21 Aug 2024 //
FIERCE BIOTECH
Windtree Therapeutics Reports Q2 2024 Results And Business Updates
20 Aug 2024 //
GLOBENEWSWIRE
Windtree Announces New Additions and Changes to Its Board of Directors
14 Aug 2024 //
GLOBENEWSWIRE
Windtree Updates On Istaroxime Development And Upcoming Trial Data
25 Jul 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Closes Private Placement Of Series C Preferred Stock
22 Jul 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Regains Compliance with Nasdaq
07 May 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Announces Reverse Stock Split
18 Apr 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Reports Q4 2023 and Year-End Results
17 Apr 2024 //
GLOBENEWSWIRE
Windtree Acquires Early-Stage, Oncology Platform and Completes $1.5M Financing
08 Apr 2024 //
GLOBENEWSWIRE
Windtree Renews Agreement with Chang Gung University
01 Feb 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Announces Engagement of Strategic Advisor
31 Jan 2024 //
GLOBENEWSWIRE
Windtree Eliminates $15M Contingent Liability to Deerfield Management Company
25 Jan 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Announces License Agreement with Lee™s Pharmaceuticals
17 Jan 2024 //
GLOBENEWSWIRE
Windtree hands over more licensing rights to Lee’s Pharma
17 Jan 2024 //
FIERCE BIOTECH
Windtree Announces Reduction In Arrythmias In A New Study With Istaroxime
02 Jan 2024 //
GLOBENEWSWIRE
Windtree Announces the Start of Patient Dosing In Phase 2 Study of Istaroxime
18 Dec 2023 //
GLOBENEWSWIRE
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
16 Nov 2023 //
GLOBENEWSWIRE
Windtree Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Windtree to Present at the Sidoti Micro Cap Conference on November 16th
08 Nov 2023 //
GLOBENEWSWIRE
Windtree to Present at ThinkEquity Conference on October 19th in New York City
12 Oct 2023 //
GLOBENEWSWIRE
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference
10 Oct 2023 //
GLOBENEWSWIRE
Windtree to Present at Dawson James Small Cap Growth Conference on October 12th
03 Oct 2023 //
GLOBENEWSWIRE
Windtree Announces Issuance of Composition of Matter Patent for SERCA2a
23 Aug 2023 //
GLOBENEWSWIRE
Windtree Therapeutics Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Windtree faces Catch-22 conundrum for hypertension med
05 Jul 2023 //
FIERCE BIOTECH
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
27 Jun 2023 //
GLOBENEWSWIRE
Windtree Announces Notice of Allowance from the US Patent
12 Jun 2023 //
GLOBENEWSWIRE
Windtree Therapeutics to Host Investor Day Focusing on Cardiogenic Shock Market
05 Jun 2023 //
GLOBENEWSWIRE
Windtree Therapeutics Reports 1Q 2023 FYR & Provides Key Business Updates
15 May 2023 //
GLOBENEWSWIRE
Windtree Announces Pub Its SEISMiC Pre Shock Study Comparing 2 dose Istaroxime
27 Apr 2023 //
GLOBENEWSWIRE
